Navigation Links
PDHI Launches Short Form of Its ConXus Profile Health Assessment
Date:3/16/2009

BERNARDSVILLE, N.J., March 16 /PRNewswire/ -- Protocol Driven Healthcare, Inc. (PDHI) now offers a short form of its health risk assessment (HRA), the ConXus(R) Profile. The shorter format facilitates completion by populations with low literacy and reduces processing costs of paper assessments. The short form does not replace the original, longer adult HRA, but joins PDHI's suite of ConXus applications, which includes assessments for students, children, and Spanish-speaking adults.

Employers can deliver both long and short forms to the same population or subgroup and can switch between long and short forms from year to year. Aggregate reports support both versions when deployed within the same population and time period.

"While the short-form HRA does not comply with NCQA HIP 1 or evalu8 standards, it does provide a robust option for employers to collect health data from hard-to-reach employees," said Jennifer Jolley, president of PDHI. "The abbreviated format also satisfies a request from many of our clients to deliver a solution that saves paper-processing costs while maintaining reporting integrity."

The short-form HRA includes about 40 instead of 70 questions. The user report shrinks to about 5 pages, and the paper questionnaire to 4 pages. The short form delivers all the functionality required to assess a participant's current health risk, omitting chronic and future disease risks on the long form.

The short-form HRA uses the same file structure as the long version, which simplifies ongoing version control. Both long and short versions of the HRA are available in English and Spanish and can be taken online or on paper.

Recent News

PDHI -- PDHI Adds Diabetes and Heart Disease Prevention to ConXus Steps Library of Action Plans http://www.pdhi.com/webnew/corporate/pressreleases/Diabetes.asp

PDHI - PDHI's Health Risk Appraisal and Consumer Health Tools Awarded NCQA HIP Certification

http://www.pdhi.com/webnew/corporate/pressreleases/NCQA.asp

About Protocol Driven Healthcare, Inc

PDHI is a healthcare technology and data processing organization that provides preventive health applications and services using the ConXus(R) health improvement platform. ConXus solutions are scalable and flexible, driving process efficiency and project control for clients. PDHI has adopted an open-systems approach, including extensive administrative tools and interfaces that allow integration of ConXus solutions into client portal environments. For more information, visit http://www.pdhi.com/.

    Contact:
    David Abel
    Vice President of Sales and Marketing
    908-315-0365, ext. 1026
    davida@pdhi.com

    Paul N. Greenwood
    Executive Vice President of Business Development
    515-277-1376, ext. 1224
    paulg@pdhi.com


'/>"/>
SOURCE Protocol Driven Healthcare, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. Enova Medical Launches Exos Corporation
4. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. ThirdBiotech Networking Group Launches
7. BioReliance Launches Next-Generation Genotoxicity Screening Service
8. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
9. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
10. Kingfisher Healthcare Launches Breakthrough Product in Europe
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... 2016 There is no saying ... the relentless pressures in pricing and lack in consumer ... circle though - numerous opportunities are up for grabs ... ActiveWallSt.com,s presents four names in this sector: Portola Pharmaceuticals ... (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/18/2016)... Calif. (PRWEB) , ... May 18, 2016 , ... ... awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last ... company that is financed by one of ACA’s member angel groups. It is the ...
(Date:5/18/2016)... Washington, PA (PRWEB) , ... May 18, 2016 ... ... at least 1,200 hospitalizations are a direct result of asthma complications.* Costing more ... challenge across the country. , “For too many, the suffering ...
Breaking Biology Technology:
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):